Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clinical trials. Whereas a role for HDAC1 and -2 in mediating components of the HDAC inhibitor response has been reported, the role of HDAC3 is unknown. Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638(N/+) mice. HDAC3 was also maximally expressed in proliferating crypt cells in normal intestine. Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increased apoptosis. Similar effects were observed for HDAC2 and, to a lesser extent, for HDAC1. HDAC3 silencing also selectively induced expression of alkaline phosphatase, a marker of colon cell maturation. Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression. However, the magnitude of the effects elicited by silencing of individual Class I HDACs was significantly less than that induced by HDAC inhibitors. These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression. These findings also demonstrate that multiple Class I HDACs are involved in repressing p21 and suggest that the growth-inhibitory and apoptotic effects induced by HDAC inhibitors are probably mediated through the inhibition of multiple HDACs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, HDAC3 has been suggested to be involved in carcinogenesis by affecting cell differentiation and apoptosis (52).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [52]
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Histones and histone modifications
Peterson, C. L., & Laniel, M.-A. (2004) · Current Biology · doi:10.1016/j.cub.2004.07.007 · Cited by 1,313
Intestinal Epithelial Cell Surface Membrane Glycoprotein Synthesis
Weiser, M. M. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44141-0 · Cited by 1,098
Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression
Laherty, C. D., Yang, W.-M., Sun, J.-M., Davie, J. R., Seto, E., & Eisenman, R. N. (1997) · Cell · doi:10.1016/s0092-8674(00)80215-9 · Cited by 938
Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2
Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., Kucherlapati, R., Lipkin, M., Yang, K., & Augenlicht, L. (2002) · Science · doi:10.1126/science.1069094 · Cited by 936
Self-citationLost in Transcription: p21 Repression, Mechanisms, and Consequences
Gartel, A. L., & Radhakrishnan, S. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3995 · Cited by 818
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760
Research works printed but not linked: 9
- Mariadason, 1997, Am. J. Physiol., 272, G705
- Heerdt, 1994, Cancer Res., 54, 3288
- Mei, 2004, Int. J. Oncol., 25, 1509
- Fischle, 2001, Biochem. Cell Biol., 79, 337, 10.1139/o01-116 · DOI · Paper page
- Mariadason, 2001, Cancer Res., 61, 3465
- Sowa, 1999, Cancer Res., 59, 4266
- Mariadason, 2003, Cancer Res., 63, 8791
- Yang, 2001, Cancer Res., 61, 565
- Bailey, 1999, Mol. Endocrinol., 13, 1155, 10.1210/mend.13.7.0305 · doi:10.1210/mend.13.7.0305 · Paper page
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
“In addition, HDAC3 is overexpressed in colon and breast tumors [11], whereas HDAC6 is highly expressed in mammary tumors, HDAC8 is overexpressed in neuroblastoma cells and HDAC11 mainly in rhabdomyosarcoma [12–14].”
BackgroundHistone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
“HDAC2 and HDAC3 proteins are increased in colon cancer samples (1, 2, 5, 27).”
BackgroundHistone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
The role of histone deacetylases (HDACs) in human cancer
Ropero, S., & Esteller, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.001 · Cited by 997
“Other studies have reported high levels of HDAC3 and HDAC6 expression in colon and breast cancer specimens, respectively (Zhang et al., 2004; Wilson et al., 2006).”
BackgroundHistone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
“Silencing of HDAC3 has been found to induce the expression of p21WAF1/CIP1 and cell cycle arrest in the G2/M phase in colon cancer cells [169].”
BackgroundHDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host
Timp, W., & Feinberg, A. P. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3486 · Cited by 586
(2011) · PubMed Central · Cited by 560
Epigenetics in cancer: Targeting chromatin modifications
Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 479
“Interestingly and in contrast to the study by Weichert and colleagues (52), knockdown of HDAC3 was more effective in inhibiting the growth of a different set of colon carcinoma cells than was knockdown of HDACs 1 or 2 (54).”
ResultWeichert, W., Röske, A., Gekeler, V, Beckers, T., Stephan, C., Jung, K., Fritzsche, F. R., Niesporek, S., Denkert, C., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604199 · Cited by 477
“An important role of class I HDACs, especially HDAC3, on cell proliferation has also been reported for other tumour entities (Wilson et al, 2006), which again makes it an interesting therapy target.”
BackgroundHDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
Yoon, S., & Eom, G. H. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.1 · Cited by 464
“Other groups have found that HDAC3 or HDAC6 was also highly overexpressed in colon and breast cancer cells, respectively.(6,12) HDACs expression is increased in solid tumors and in hematological cancers, which correlates with a poor prognosis.”
BackgroundLauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
“Moreover, HDAC3 has been suggested to be involved in carcinogenesis by affecting cell differentiation and apoptosis (52).”
BackgroundHDAC expression and clinical prognosis in human malignancies
Weichert, W. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.10.047 · Cited by 409
Histone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer
Noonan, E. J., Place, R. F., Pookot, D., Basak, S., Whitson, J. M., Hirata, H., Giardina, C., & Dahiya, R. (2009) · Oncogene · doi:10.1038/onc.2009.19 · Cited by 396
“siRNA studies have been crucial to understanding the importance of individual isoforms of class I HDACs and have helped characterize their function in proliferation and tumorigenesis (Wilson et al., 2006; Spurling et al., 2008; Weichert et al., 2008b), including HDAC-1 (Glaser et al.”
BackgroundBhaskara, S., Chyla, B. J., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z.-W., & Hiebert, S. W. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.030 · Cited by 372
Weichert, W., Röske, A., Niesporek, S., Noske, A., Buckendahl, A.-C., Dietel, M., Gekeler, V., Boehm, M., Beckers, T., & Denkert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0990 · Cited by 361
Hdac3 is essential for the maintenance of chromatin structure and genome stability
Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353
“Although HDAC3 has been suggested to be overexpressed in colorectal carcinoma (Spurling et al., 2008; Wilson et al., 2006), it”
InfluentialSelf-citationHistone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Carew, J. S., Giles, F. J., & Nawrocki, S. T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.037 · Cited by 421
Fournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2026 · Cited by 332
Fetahu, I. S., Höbaus, J., & Kállay, E. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00164 · Cited by 313
“In colorectal cancer patients HDAC1, 2, and 3 are overexpressed, and high HDAC1 and 2 expression is linked with reduced patient survival (Zhu et al., 2004; Wilson et al., 2006).”
BackgroundHDAC inhibitor‐based therapies: Can we interpret the code?
New, M., Olzscha, H., & La Thangue, N. B. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310
“It was shown that inhibition of HDAC3 or reduced levels of HDAC3 lead to reduced phosphorylation at S10 and aberrant mitosis (Wilson et al., 2006).”
BackgroundHistone Deacetylases and Mechanisms of Regulation of Gene Expression
Chen, H. P., Zhao, Y. T., & Zhao, T. C. (2015) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.2015012997 · Cited by 306
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Licciardi, P., Ververis, Hiong, & Karagiannis (2013) · Biologics: Targets and Therapy · doi:10.2147/btt.s29965 · Cited by 274
“For example, overexpression of specific HDACs has been identified in a range of human cancers, including HDAC1 in gastric(26) and prostate(27) cancer, HDAC1 and -6 in breast cancer,(28,29) and HDAC2 and -3 in colorectal cancer.(30,31) Furthermore, murine knockout models have given rise to possible side effects from th…”
Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation
Senese, S., Zaragoza, K., Minardi, S., Muradore, I., Ronzoni, S., Passafaro, A., Bernard, L., Draetta, G. F., Alcalay, M., Seiser, C., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00494-07 · Cited by 254
“overexpression of HDAC3 is seen with colon tumors (54).”
BackgroundMicrobiota-derived metabolite promotes HDAC3 activity in the gut
Wu, S.-E., Hashimoto-Hill, S., Woo, V., Eshleman, E. M., Whitt, J., Engleman, L., Karns, R., Denson, L. A., Haslam, D. B., & Alenghat, T. (2020) · Nature · doi:10.1038/s41586-020-2604-2 · Cited by 249
Arts, J., King, P., Marin, A., Floren, W., Belin, A., Janssen, L., Pilatte, I., Roux, B., Decrane, L., Gilissen, R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0547 · Cited by 224
HDACs and HDAC inhibitors in colon cancer
Mariadason, J. M. (2008) · Epigenetics · doi:10.4161/epi.3.1.5736 · Cited by 222
Self-citationHDAC3: taking the SMRT-N-CoRrect road to repression
Karagianni, P., & Wong, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210612 · Cited by 222
“Differential display cloning of HDAC3 from stimulated T cells alluded to a possible role of this enzyme in cell cycle progression, further supported by the fact that both overexpression and downregulation of this molecule causes G2/M arrest (Dangond et al., 1998; Wilson et al., 2006).”
InfluentialTotal Synthesis and Molecular Target of Largazole, a Histone Deacetylase Inhibitor
Ying, Y., Taori, K., Kim, H., Hong, J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8013727 · Cited by 222
Histone deacetylase inhibitors and cell death
Zhang, J., & Zhong, Q. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1656-6 · Cited by 214
“For example, overexpression of HDAC1 has been reported in prostate, gastric and breast cancer cells [25-27] and increased expression of HDAC2 and HDAC3 has been observed in colorectal cancer [28, 29].”
HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21
Wilson, A. J., Byun, D.-S., Nasser, S., Murray, L. B., Ayyanar, K., Arango, D., Figueroa, M., Melnick, A., Kao, G. D., Augenlicht, L. H., et al. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-02-0139 · Cited by 214
Self-citationPang, M., Kothapally, J., Mao, H., Tolbert, E., Ponnusamy, M., Chin, Y. E., & Zhuang, S. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00282.2009 · Cited by 211
“Among eight enzymes in class I and II HDACs, HDAC1, HDAC2, and HDAC3 are ubiquitously expressed and have been reported to mediate proliferation and differentiation in tumor cells (25, 41, 46).”
BackgroundHDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
Bolden, J. E., Shi, W., Jankowski, K., Kan, C.-Y., Cluse, L., Martin, B. P., MacKenzie, K. L., Smyth, G. K., & Johnstone, R. W. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.9 · Cited by 192
Hatayama, H., Iwashita, J., Kuwajima, A., & Abe, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.025 · Cited by 196
Extracellular superoxide dismutase and its role in cancer
Griess, B., Tom, E., Domann, F., & Teoh-Fitzgerald, M. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.013 · Cited by 195
Journal of Pharmaceutical and Biomedical Sciences
(2016) · Journal of Pharmaceutical and Biomedical Sciences · doi:10.20936/jpbms · Cited by 195
Histone deacetylases and the immunological network: implications in cancer and inflammation
Villagra, A., Sotomayor, E. M., & Seto, E. (2010) · Oncogene · doi:10.1038/onc.2009.334 · Cited by 192
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191
Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer
Park, C. (2011) · Oncology Reports · doi:10.3892/or.2011.1236 · Cited by 183
Wang, Z., Cao, H., Sun, Y., Li, X., Chen, F., Carles, A., Li, Y., Ding, M., Zhang, C., Deng, X., et al. (2013) · The Plant Cell · doi:10.1105/tpc.112.108191 · Cited by 183
“SIN3 has an important role in the regulation of centromeres, the cell cycle, and chromatin remodeling in several organisms (Kawaguchi et al., 2003; Sakuma et al., 2006; Wilson et al., 2006).”
BackgroundRecent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Nepali, K., & Liou, J.-P. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00721-x · Cited by 178
The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
Bassett, S., & Barnett, M. (2014) · Nutrients · doi:10.3390/nu6104273 · Cited by 178
“[99]”
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Liu, T., Wan, Y., Xiao, Y., Xia, C., & Duan, G. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00491 · Cited by 186
Ma, P., & Schultz, R. M. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.04.011 · Cited by 176
“In addition, HDACs control gene transcription by regulating acetylation of DNA sequence-specific transcription factors (Gu and Roeder, 1997; Wilson et al., 2006).”
BackgroundA novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity
Li, Y., Kao, G. D., Garcia, B. A., Shabanowitz, J., Hunt, D. F., Qin, J., Phelan, C., & Lazar, M. A. (2006) · Genes & Development · doi:10.1101/gad.1455006 · Cited by 176
Histone Deacetylases: A Saga of Perturbed Acetylation Homeostasis in Cancer
Parbin, S., Kar, S., Shilpi, A., Sengupta, D., Deb, M., Rath, S. K., & Patra, S. K. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413506582 · Cited by 172
“Experimental results indicate that colon cancer cells overexpress HDAC3 with a corresponding inhibition of p21 expression (Wilson et al. 2006; Spurling et al. 2008).”
BackgroundHDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA
Fritsche, P., Seidler, B., Schüler, S., Schnieke, A., Göttlicher, M., Schmid, R. M., Saur, D., & Schneider, G. (2009) · Gut · doi:10.1136/gut.2009.180711 · Cited by 167
“The functions of HDAC2 are highly cell type and tissue specific. In vivo, a recent report demonstrates that HDAC2 knockout mice are characterised by increased cardiac cell proliferation and apoptosis, a phenotype that was not observed in non-cardiac tissues.”
BackgroundHDACi – Targets beyond chromatin
Buchwald, M., Krämer, O. H., & Heinzel, T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.028 · Cited by 159
Lucio-Eterovic, A. K., Cortez, M. A., Valera, E. T., Motta, F. J., Queiroz, R. G., Machado, H. R., Carlotti, C. G., Neder, L., Scrideli, C. A., & Tone, L. G. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-243 · Cited by 156
“[8] have suggested that multiple class I HDAC members are also involved in repressing p21 and that the growth inhibitory and apoptotic effects induced by HDAC inhibitors are probably mediated through the inhibition of multiple HDACs.”
BackgroundMottet, D., Pirotte, S., Lamour, V., Hagedorn, M., Javerzat, S., Bikfalvi, A., Bellahcène, A., Verdin, E. M., & CASTRONOVO, V. (2008) · Oncogene · doi:10.1038/onc.2008.371 · Cited by 180
“HDAC4 represses p21 in cancer cells in vitro in a Sp1-dependent manner Although most reports demonstrated that HDAC inhibitors induced p21 expression in an Sp1/Sp3-dependent manner (Nakano et al., 1997; Sowa et al., 1997, 1999; Han et al., 2001; Wilson et al., 2006), a role for p53 in HDAC-associated p21 expression ha…”
BackgroundInfluentialThe role of histone deacetylases in prostate cancer
Abbas, A., & Gupta, S. (2008) · Epigenetics · doi:10.4161/epi.3.6.7273 · Cited by 167
Dietary Manipulation of Histone Structure and Function
Delage, B., & Dashwood, R. H. (2008) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155354 · Cited by 155
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X. (2013) · Oncogene · doi:10.1038/onc.2012.81 · Cited by 153
Development of histone deacetylase inhibitors for cancer treatment
Marchion, D., & Münster, P. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.583 · Cited by 149
Hayashi, A., Horiuchi, A., Kikuchi, N., Hayashi, T., Fuseya, C., Suzuki, A., Konishi, I., & Shiozawa, T. (2010) · International Journal of Cancer · doi:10.1002/ijc.25151 · Cited by 145
Next-generation of selective histone deacetylase inhibitors
Yang, F., Zhao, N., Ge, D., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra02985k · Cited by 155
Butyrate-producing bacteria and the gut-heart axis in atherosclerosis
Chen, W., Zhang, S., Wu, J., Ye, T., Wang, S., Wang, P., & Xing, D. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.04.037 · Cited by 142
The role of vitamin D and VDR in carcinogenesis: Through epidemiology and basic sciences
Bandera-Merchán, B., Morcillo, S., Martín‐Núñez, G. M., Tinahones, F. J., & Macías‐González, M. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.11.020 · Cited by 157
Salimi, V., Shahsavari, Z., Safizadeh, B., Hosseini, A., Khademian, N., & Tavakoli‐Yaraki, M. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0593-4 · Cited by 145
“It has been shown that p21 is not the target of HDACi for processing apoptosis [26].”
Zupkovitz, G., Grausenburger, R., Brunmeir, R., Senese, S., Tischler, J., Jurkin, J., Rembold, M., Meunier, D., Egger, G., Lagger, S., et al. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01500-09 · Cited by 138
“In addition, other HDACs, such as HDAC2, HDAC3, and HDAC4, were identified as regulator of the p21 gene (30, 53, 54).”
BackgroundMicroRNA-449 in cell fate determination
Lizé, M., Klimke, A., & Dobbelstein, M. (2011) · Cell Cycle · doi:10.4161/cc.10.17.17181 · Cited by 148
Tan, L. T. (2010) · Journal of Applied Phycology · doi:10.1007/s10811-010-9506-x · Cited by 148
“It has been observed that the overexpression of class I HDAC enzymes, such as HDAC1 and HDAC3, occurs in colon and prostate tumors, respectively (Halkidou et al. 2004; Wilson et al. 2006).”
BackgroundNovotny-Diermayr, V., Sangthongpitag, K., Hu, C. Y., Wu, X., Sausgruber, N., Yeo, P., Greicius, G., Pettersson, S., Liang, A. L., Loh, Y. K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0689 · Cited by 131
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B‐ and T‐cell lymphomas
Marquard, L., Poulsen, C. B., Gjerdrum, L. M. R., Brown, P. D. N., Christensen, I. J., Jensen, P. B., Sehested, M., Johansen, P., & Ralfkiaer, E. M. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03290.x · Cited by 144
Nian, H., Delage, B., Pinto, J. T., & Dashwood, R. H. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn165 · Cited by 139
“Indeed, while direct interactions between Sp1/Sp3 and p300/cyclic AMP response element-binding protein CBP were associated with promoter activation upon HDAC inhibitor treatment (57), Sp1/Sp3 also mediated the repression of P21WAF1 by HDAC1–3 in colon cancer cells ( 58 ).”
BackgroundHistone deacetylase 3 (hdac3) is specifically required for liver development in zebrafish
Farooq, M., Sulochana, K. N., Pan, X., To, J., Sheng, D., Gong, Z., & Ge, R. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.02.034 · Cited by 136
HDAC3 overexpression and colon cancer cell proliferation and differentiation
Spurling, C. C., Godman, C. A., Noonan, E. J., Rasmussen, T. P., Rosenberg, D. W., & Giardina, C. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20373 · Cited by 123
“HDACs in regulating p21 in colon cancer cells has generated some conflicting data, with roles for both HDACs 2 and 3 reported [25,31].”
BackgroundLi, W., Sun, W. Y., Liu, L., Yang, F., Li, Y., Chen, Y., Fang, J., Zhang, W., Wu, J., & Zhu, Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902667 · Cited by 139
Rajendran, P., Delage, B., Dashwood, W. M., Yu, T.-W., Wuth, B., Williams, D. E., Ho, E., & Dashwood, R. H. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-68 · Cited by 124
“HDACs can be overexpressed in colorectal cancers and in several other cancer types [13-18].”
BackgroundWang, Y., Stowe, R. L., Pinello, C. E., Tian, G., Madoux, F., Li, D., Zhao, L. Y., Li, J.-L., Wang, Y., Wang, Y., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.12.015 · Cited by 122
“In particular, the roles of HDAC1, HDAC2, and HDAC3 in promoting cancer progression have been extensively documented (Muller et al., 2013; New et al., 2012; Wilson et al., 2006).”
Ouaïssi, M., Sielezneff, I., Silvestre, R., Sastre, B., Bernard, J., Simony-Lafontaine, J., Payan, M. J., Dahan, L., Pirró, N., Seitz, J. F., et al. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9940-z · Cited by 131
Caslini, C., Hong, S., Ban, Y. J., Chen, X. S., & Ince, T. A. (2019) · Oncogene · doi:10.1038/s41388-019-0897-0 · Cited by 121
An Epigenetic Role of Mitochondria in Cancer
Liu, Y., Chen, C., Wang, X., Sun, Y., Zhang, J., Chen, J., & Shi, Y. (2022) · Cells · doi:10.3390/cells11162518 · Cited by 141
Protein arginine deiminase 4: a target for an epigenetic cancer therapy
Slack, J. L., Causey, C. P., & Thompson, P. R. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0480-x · Cited by 120
“SAHA, a class I/II HDAC inhibitor, served as the positive control as this compound is known to trigger the differentiation of several cancerous cell lines, including HT-29 cells [32].”
Felice, C., Lewis, A., Armuzzi, A., Lindsay, J. O., & Silver, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13008 · Cited by 120
“effect on cell growth and proliferation in human colon cancer.(36) Similar findings have been also described for HDAC2.”
ResultHDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
Chou, C., Wu, M., Huang, W., & Chen, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018087 · Cited by 130
“In HCT116 cells, p21 is induced and the cell cycle is arrested in G2/ M phase by silencing class I HDACs, especially HDAC3 [17].”
BackgroundInfluentialAnticolon Cancer Activity of Largazole, a Marine-Derived Tunable Histone Deacetylase Inhibitor
Liu, Y., Salvador, L. A., Byeon, S., Ying, Y., Kwan, J. C., Law, B. K., Hong, J., & Luesch, H. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.172387 · Cited by 130
Trivedi, C. M., Lu, M. M., Wang, Q., & Epstein, J. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803686200 · Cited by 118
Rajendran, P., Kidane, A. I., Yu, T., Dashwood, W., Bisson, W. H., Löhr, C. V., Ho, E., Williams, D. E., & Dashwood, R. H. (2013) · Epigenetics · doi:10.4161/epi.24710 · Cited by 132
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
Peng, X., Sun, Z., Kuang, P., & Chen, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112831 · Cited by 121
López-Soto, A., Folgueras, A. R., Seto, E., & Gonzalez, S. (2009) · Oncogene · doi:10.1038/onc.2009.117 · Cited by 118
“To test whether the lack of response of ULBP2 and ULBP3 to HDAC3 was specific to HeLa cells, we overexpressed HDAC3 in HCT-116, a cell line which has been reported that this HDAC represses the p21 promoter activity (Wilson et al., 2006).”
BackgroundInfluentialTsai, S.-Y. A., Chuang, J.-Y., Tsai, M.-S., Wang, X.-F., Xi, Z.-X., Hung, J.-J., Chang, W.-C., Bonci, A., & Su, T.-P. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518894112 · Cited by 116
“The transcription factor Sp3 may thus be involved for two reasons: Sp3 binds GC-boxes on the MAOB core promoter for the regulation of the MAOB expression (39), and Sp3 recruits HDAC1, HDAC2, or HDAC3 to the promoter for histone deacetylation and gene silencing (40, 41).”
BackgroundExpression and Function of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts
HORIUCHI, M., MORINOBU, A., CHIN, T., SAKAI, Y., KUROSAKA, M., & KUMAGAI, S. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081115 · Cited by 114
Li, Y., Li, X., & Guo, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1924 · Cited by 116
“The class I HDACs have been linked to the transcriptional repression of the cyclin-dependent kinase (cdk) inhibitor p21 (27), and the HDAC inhibitors have been shown to induce cell cycle arrest by activating the expression of p21 and p27 (28, 29).”
BackgroundDietary Inhibitors of Histone Deacetylases in Intestinal Immunity and Homeostasis
Schilderink, R., Verseijden, C., & de Jonge, W. J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00226 · Cited by 115
“Hence, repression of the activity of the proximal p21 promoter is likely mediated by HDAC4 through association with the catalytically active HDAC3, within the N-CoR/SMRT co-repressor complex (69, 71).”
BackgroundThe synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
Chao, M.-W., Lai, M.-J., Liou, J.-P., Chang, Y.-L., Wang, J.-C., Pan, S.-L., & Teng, C.-M. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0176-7 · Cited by 109
“HDAC overexpression in many cancers has also been reported [13–15].”
BackgroundThe Biology of HDAC in Cancer: The Nuclear and Epigenetic Components
Hagelkrüys, A., Sawicka, A., Rennmayr, M., & Seiser, C. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-21631-2_2 · Cited by 118
“In the HCT-166 cell line, siRNA-mediated depletion of HDAC1, 2, and 3 resulted in reduction of cell growth with the greatest effect seen for HDAC3 (Wilson et al. 2006).”
BackgroundInfluentialHistone Deacetylase Inhibitors: Biology and Mechanism of Action
Mehnert, J. M., & Kelly, W. K. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e31803c72ba · Cited by 124
Marquard, L., Gjerdrum, L. M., Christensen, I. J., Jensen, P. B., Sehested, M., & Ralfkiaer, E. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03109.x · Cited by 107
“Furthermore, HDAC1, HDAC2 and HDAC3 are up-regulated in colonic tumours compared with adjacent normal mucosa.(24,52,53) Up-regulation of HDAC1 and nuclear accumulation of HDAC4 have been reported in primary and hormone refractory prostatic cancer compared with benign prostatic hyperplasia.”
BackgroundWu, L.-M., Yang, Z., Zhou, L., Zhang, F., Xie, H., Feng, X., Wu, J., & Zheng, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014460 · Cited by 106
“Supporting our results, a previously published study demonstrated similar effects in colon cancer cell lines [26].”
ResultRetractedSu, J. M. F., Li, X., Thompson, P., Ou, C., Ingle, A. M., Russell, H. V., Lau, C. C., Adamson, P. C., & Blaney, S. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0738 · Cited by 113
“Pre-clinical studies (8, 9, 11, 16-18) have shown that histone hyper-acetylation after VPA treatment appears to be critical for its anti-cancer effect.”
Jung, S.-B., Kim, C., Naqvi, A., Yamamori, T., Mattagajasingh, I., Hoffman, T. A., Cole, M. P., Kumar, A., DeRicco, J. S., Jeon, B. H., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.222968 · Cited by 108
Mattera, L., Escaffit, F., Pillaire, M., Sèlves, J., Tyteca, S., Hoffmann, J.-S., Gourraud, P., Chevillard, M., Cazaux, C., & Trouche, D. (2009) · Oncogene · doi:10.1038/onc.2008.499 · Cited by 113
“Also shown is a histone deacetylase (HDAC) western blot as a loading control (please note that HDAC1/2 expression is higher in cancer cell lines, in agreement with previous findings that HDAC1/2 mRNA is overexpressed in colon carcinoma (Wilson et al., 2006)).”
ResultHistone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer
Botrugno, O. A., Santoro, F., & Minucci, S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.027 · Cited by 114
Wang, Y., Frank, D. B., Morley, M. P., Zhou, S., Wang, X., Lu, M. M., Lazar, M. A., & Morrisey, E. E. (2016) · Developmental Cell · doi:10.1016/j.devcel.2015.12.031 · Cited by 102
“Previous studies have shown that one common function of Hdac proteins is to regulate cell proliferation and survival through direct de-repression of cell-cycle inhibitors (Montgomery et al., 2007; Wilson et al., 2006; Yamaguchi et al., 2010).”
Shan, X., Fu, Y.-S., Aziz, F., Wang, X.-Q., Yan, Q., & Liu, J.-W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115401 · Cited by 101
Haery, L., Thompson, R. C., & Gilmore, T. D. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.65 · Cited by 111
Metadata
- Authors
- Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M.
- Affiliations
- Albert Einstein College of Medicine (US)
- Kyoto Prefectural University of Medicine (JP)
- Vall d'Hebron Institut de Recerca (ES)
- Corresponding author
- Mariadason, John M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 281
- Issue
- 19
- Pages
- 13548-13558
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2105095164
- Semantic Scholar
- c2db47db00c10ecf03aae7c6c6f1c3b194c81502
- Cited by
- 575
- References
- 43
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 31 · 2023: 28 · 2022: 25 · 2021: 18 · 2020: 30 · 2019: 26 · 2018: 27 · 2017: 30 · 2016: 30 · 2015: 38 · 2014: 32 · 2013: 40 · 2012: 28
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5273 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA088104, R01CA100823, CA88104-04, CA100823-03)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- HDAC3, class I HDACs, colon cancer, histone deacetylase inhibitors, apoptosis, alkaline phosphatase, duodenal adenoma, crypt cells, gene silencing, tumor suppressor
- MeSH terms
- Cell Differentiation, Colon, Colonic Neoplasms, Histone Deacetylases, Humans, Time Factors, Down-Regulation, Up-Regulation, Gene Expression Regulation, Enzymologic, Apoptosis, Caco-2 Cells, Gene Silencing, HCT116 Cells, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p21, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.